- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02532218
Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia (REASCEND)
Randomized Evaluation of ARI-3037MO, to Suppress LDL Cholesterol in Patients With Dyslipidemia
Study Overview
Detailed Description
This study is a prospective, multi-center, randomized, double-blinded, controlled clinical trial. The study will compare two arms: ARI-3037MO 3 g BID vs. placebo.
Subjects who sign informed consent will be enrolled and will undergo all Visit 1 assessments. Following evaluation of Visit 1 laboratory assays, eligible subjects will receive a phone call (Visit 2) during which they will be instructed to begin the lifestyle modification and enter a 4- to 6-week lead-in period (6-week wash-out period for subjects to wash out of non-statin lipid-lowering therapy [subjects may remain on statins during this period], 4 weeks for subjects receiving statins only or not receiving any lipid-lowering therapy), followed by a qualifying fasting LDL-C measurement at Visit 3. After the lead-in period, if the LDL-C level at Visit 3 is not ≥ 100 mg/dL, an additional week will be allowed for another qualifying measurement at a subsequent visit (Visit 3.1). If performed, the LDL-C level at Visit 3.1 must be ≥ 100 mg/dL in order for the subject to continue participation in the study. Qualifying subjects will be randomized in a 1:1 manner at Visit 4 to one of two arms of the double-blind, 24-week efficacy and safety assessment phase. Randomization will be stratified by background statin therapy status at Visit 1 (yes/no). Baseline lipid levels will be defined as lipid levels at Visit 4. End-of-study lipid levels will be defined as the lipid levels at Visit 7 (Week 24).
A final closeout and safety assessment visit will be held at 26 weeks post randomization (Visit 8).
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Chino, California, United States, 91710
- Catalina Reserch Institute, LLC
-
-
Florida
-
Ft Lauderdale, Florida, United States, 33306
- S&W Clinical Reserch
-
Jacksonvile, Florida, United States, 32216
- Jacksonville Center for Clinical Research
-
Port Orange, Florida, United States, 32127
- Progressive Medical Research
-
-
Georgia
-
Marietta, Georgia, United States, 30060
- Sestron Clinical Research 833 Campbell Hill Street Suite 230
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- Midwest Institute for Clinical Research
-
-
Kentucky
-
Louisville, Kentucky, United States, 40213
- Louisville Metabolic and Atherosclerosis Research Center
-
-
New York
-
Rochester, New York, United States, 14069
- Rochester clinical Research,Inc
-
-
Ohio
-
Cincinnati, Ohio, United States, 45246
- Sterling Research Group, Ltd
-
Cincinnati, Ohio, United States, 45227
- Metabolic and Atherosclerosis Research Center
-
Cincinnati, Ohio, United States, 45219
- Sterling Research Group Ltd
-
Cincinnati, Ohio, United States, 45219
- The Carl and Edyth Lindner Center for Reserch and education at the Christ Hospital
-
Cincinnati, Ohio, United States, 45245
- IVA reserch
-
Lyndhurst, Ohio, United States, 44124
- Ohio Clinical Research-Lyndhurst
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73103
- COR Clinical Research
-
-
Oregon
-
Eugene, Oregon, United States, 97404
- Willamette Valley Clinical Studies
-
-
Virginia
-
Norfolk, Virginia, United States, 23502
- Health Research of Hampton Roads - Norfolk
-
Richmond, Virginia, United States, 23294
- National Clinical Research inc
-
-
Washington
-
Renton, Washington, United States, 98057
- Raninier Clinical Reserach
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years at screening.
- Women of childbearing potential, must agree to use 2 medically accepted, effective methods of birth control. Females who are postmenopausal must have been postmenopausal for > 1 year if they wish not to use contraceptives. If postmenopausal status is questionable, the subject's follicle-stimulating hormone level must be elevated and consistent with postmenopausal levels (i.e., > 40 IU/L); otherwise these subjects must agree to use contraceptives listed above.
- Male subjects with sexual partners of childbearing potential must be surgically sterile or using an acceptable method of contraception from the time of screening through 12 weeks after last dose of study drug to prevent pregnancy in a partner.
- Female subjects of childbearing potential (including females with questionable postmenopausal status) must have a negative pregnancy test prior to dosing.
- LDL-C level: ≥ 100 mg/dL.
- Triglycerides (TG) ≤ 300 mg/dL.
- High-density lipoprotein cholesterol (HDL-C) level < 45 mg/dL in men and < 50 mg/dL in women.
- Subject understands the trial requirements and the treatment procedures, is willing to comply with all protocol-required follow-up evaluation and provides written informed consent
- Subjects will be managed according to current standard of care. Subjects taking statin therapy will remain on their statin background therapy and must be on a stable dose, defined as no changes in the dose of statin in the 3 months prior to screening, and must be willing and able to remain on that dose for the duration of the study.
Exclusion Criteria:
- Subjects treated with any statin at its maximally approved dose will be excluded from the study.
- Body mass index (BMI) > 45 kg/m2.
- Weight change ≥ 3 kg during the lead-in period.
- Uncontrolled diabetes, defined as glycosylated hemoglobin (HbA1C) > 9.5%.
- Contraindication to niacin treatment (prior flushing is not regarded as a contraindication to niacin treatment).
- History of stroke, myocardial infarction, life-threatening arrhythmia, or having had coronary vascularization within 6 months before screening.
- Thyroid-stimulating hormone ≥ 1.5 times the upper limit of normal (ULN).
- Clinical evidence of hypothyroidism or thyroid hormonal therapy that has not been stable for ≥ 6 weeks before screening.
- Creatine kinase concentration ≥ 3 times the ULN.
Known, active liver disease, including but not limited to
- Confirmed alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase ≥ 2 times the ULN, or bilirubin ≥ 1.5 times the ULN.
- Hepatitis C (anti-hepatitis C virus immunoglobulin G +).
- Hepatitis B (hepatitis B surface antigen +, anti-hepatitis B core antigen immunoglobulin M +).
- Blood donation of ≥ 1 pint (0.5 L) within 30 days before screening or plasma donation within 7 days before screening.
- Known nephrotic syndrome or ≥ 3 g/day proteinuria.
- Past organ transplant or on a waiting list for an organ transplant.
- Subject is currently receiving chemotherapy; or has received chemotherapy within the 30 days prior to screening; or is scheduled to receive chemotherapy during the course of the study.
- Other serious medical illness (e.g., cancer, congestive heart failure) with estimated life expectancy of less than 12 months.
- Problems with substance abuse, which, in the opinion of the Investigator, might affect study compliance.
- Planned procedure that may cause non-compliance with the protocol or confound data interpretation.
- Participation in another investigational drug trial in the past 30 days or current participation in a device trial that has not reached its primary endpoint.
- Female subjects who are pregnant, breastfeeding, or planning to become pregnant during the study or within 12 weeks after last dose of study drug.
- Estimated glomerular filtration rate < 60 mL/min/1.73 m2. -
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active
ARI-3037MO (niacin analog) 3g bid for 24 wks
|
Lipid lowering treatment Statins
|
Placebo Comparator: Placebo
Matching Placebo 3g bid for 24 wks
|
Lipid lowering treatment Statins
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
LDL-c
Time Frame: 24 wks
|
change in LDL cholesterol level
|
24 wks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HDL-c
Time Frame: 24 wks
|
Change in HDL cholesterol
|
24 wks
|
TG
Time Frame: 24 wks
|
Change in triglyceride levels
|
24 wks
|
HbA1C
Time Frame: 24 wks
|
Change in hemoglobin A1C
|
24 wks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ARI-3037MO-005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperlipidemia
-
Drug Commission of the German Medical AssociationMadaus AGTerminatedHypercholesterolemia | Combined Hyperlipidemia
-
Misr University for Science and TechnologyActive, not recruiting
-
DongKoo Bio & PharmaUnknownHyperlipidemia, HypertriglyceridemiaKorea, Republic of
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHypercholesterolemia and HyperlipidemiaChina
-
Jeil Pharmaceutical Co., Ltd.CompletedHypertension With HyperlipidemiaKorea, Republic of
-
PfizerWithdrawnPrimary Hyperlipidemia or Mixed DyslipidemiaChina
-
ShionogiIntegriumCompletedCombined HyperlipidemiaUnited States
-
IlDong Pharmaceutical Co LtdCompletedHypertension With HyperlipidemiaKorea, Republic of
-
HK inno.N CorporationCompletedHypertension With Hyperlipidemia
-
LG Life SciencesCompletedHypertension, HyperlipidemiaKorea, Republic of
Clinical Trials on ARI-3037MO
-
Arisaph Pharmaceuticals IncUnknownNonalcoholic SteatohepatitisUnited States
-
Arisaph Pharmaceuticals IncBaim Institute for Clinical ResearchCompletedHypertriglyceridemiaUnited States
-
University Medical Center GroningenStichting Hemato-Oncologie voor Volwassenen NederlandRecruitingNHL | DLBCL - Diffuse Large B Cell LymphomaNetherlands
-
Sara V. LatorreInstituto de Salud Carlos III; Institut d'Investigacions Biomèdiques August...Active, not recruiting
-
PfizerCVS CaremarkCompleted
-
CHU de Quebec-Universite LavalCompletedAcute Respiratory InfectionsCanada
-
Gangnam Severance HospitalRecruitingProstatic Hyperplasia | Prostatic Hypertrophy | Prostate HyperplasiaKorea, Republic of
-
Malaria ConsortiumUNICEF; Ministry of Health, Ethiopia; La Caixa FoundationTerminatedPneumonia ChildhoodEthiopia
-
University of PennsylvaniaUniversity of California, San Francisco; Geisinger ClinicCompletedAcute Respiratory Tract Infection
-
Rahul AggarwalJanssen Scientific Affairs, LLCActive, not recruitingProstate Cancer | Small Cell Carcinoma | Small Cell Neuroendocrine CarcinomaUnited States